Get the Stockscreener App
93.89
2.16%
1.985
Palvella Therapeutics Inc stock is traded at $93.89, with a volume of 173.41K.
It is up +2.16% in the last 24 hours and up +25.09% over the past month.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
See More
Previous Close:
$91.91
Open:
$93.24
24h Volume:
173.41K
Relative Volume:
0.86
Market Cap:
$1.11B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-6.10%
1M Performance:
+25.09%
6M Performance:
+294.35%
1Y Performance:
+0.00%
1-Day Range:
$90.09
$95.00
1-Week Range:
$89.94
$106.71
52-Week Range:
$11.17
$106.71
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Name
Palvella Therapeutics Inc
Sector
Industry
Phone
(484) 253-1461
Address
353 W. LANCASTER AVENUE, WAYNE
Compare PVLA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
93.89 | 1.09B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-25 | Initiated | Craig Hallum | Buy |
| Nov-19-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-09-25 | Initiated | Oppenheimer | Outperform |
| Aug-06-25 | Initiated | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Apr-09-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-26-25 | Initiated | Stifel | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-20-25 | Initiated | Canaccord Genuity | Buy |
| Feb-05-25 | Initiated | TD Cowen | Buy |
| Dec-26-24 | Initiated | H.C. Wainwright | Buy |
| Dec-18-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-30-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-19 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Initiated | Jefferies | Buy |
| Jan-16-18 | Reiterated | H.C. Wainwright | Buy |
| May-30-17 | Initiated | Rodman & Renshaw | Buy |
| Aug-05-16 | Resumed | ROTH Capital | Buy |
| Aug-12-15 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-15 | Initiated | Oppenheimer | Outperform |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
View All
Palvella Therapeutics Inc Stock (PVLA) Latest News
Clear Street initiates Palvella Therapeutics stock with Buy rating, $200 target - Investing.com Canada
Will Palvella Therapeutics Inc. (PI6) stock beat revenue estimates2025 Price Targets & Long-Term Investment Growth Plans - Newser
How Palvella Therapeutics Inc. (PI6) stock compares with top peersJuly 2025 Reactions & Safe Capital Preservation Plans - Newser
Lymphatic Malformations Market Expected to Experience Major - openPR.com
Can Palvella Therapeutics Inc. stock sustain revenue growth2025 Volatility Report & Risk Managed Investment Signals - Newser
Palvella Therapeutics (NASDAQ:PVLA) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Will Palvella Therapeutics Inc. (PI6) stock keep high P E multiplesMarket Growth Summary & Risk Managed Trade Strategies - Newser
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives $117.33 Consensus PT from Brokerages - Defense World
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 7.9%Should You Sell? - MarketBeat
Tech Rally: How risky is Palvella Therapeutics Inc stock now2025 Geopolitical Influence & Technical Entry and Exit Tips - BỘ NỘI VỤ
Palvella Therapeutics (PVLA) Stock Analysis Report | Financials & Insights - Benzinga
Will Palvella Therapeutics Inc. stock benefit from automationJuly 2025 Rallies & High Yield Stock Recommendations - Newser
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Tiny Biotech’s Big Bet On Rare Skin Diseases - Finimize
Will Palvella Therapeutics Inc. stock continue upward momentumJuly 2025 Market Mood & Weekly Consistent Profit Watchlists - BỘ NỘI VỤ
Palvella Therapeutics stock hits 52-week high at 104.99 USD By Investing.com - Investing.com Australia
Can Palvella Therapeutics Inc. (PI6) stock survive global slowdownMarket Volume Report & Free Real-Time Market Sentiment Alerts - moha.gov.vn
Stifel Maintains Palvella Therapeutics (PVLA) Buy Recommendation - Nasdaq
The Short-Sellers May Be Right About This Red-Hot Pharma Stock - Yahoo Finance
Palvella Therapeutics stock price target raised to $145 by Stifel - Investing.com Canada
Palvella Therapeutics COO Kathleen Goin Sells All Directly Owned Common Stock - TradingView
Is Frog Cellsat Limited Positioned to Benefit From Secular ShiftsCandlestick Trading Patterns & Discover Your Financial Freedom Formula - earlytimes.in
Palvella Therapeutics stock hits 52-week high at $98.60 By Investing.com - Investing.com Canada
Will Palvella Therapeutics Inc. (PI6) stock rise with strong economyQuarterly Portfolio Report & Stepwise Trade Signal Implementation - newser.com
Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up Following Analyst Upgrade - Defense World
Palvella Therapeutics (NASDAQ:PVLA) Stock Rating Upgraded by Raymond James Financial - Defense World
Palvella Therapeutics stock hits 52-week high at $98.60 - Investing.com India
Palvella Therapeutics Inc (PVLA) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Why Palvella Therapeutics Inc. stock remains a top recommendationRecession Risk & Low Drawdown Investment Ideas - newser.com
First Light Asset Management, LLC's Palvella Therapeutics Inc(PVLA) Holding History - GuruFocus
Will Palvella Therapeutics Inc. stock continue dividend increasesWeekly Earnings Recap & Risk Adjusted Buy/Sell Alerts - newser.com
Raymond James Upgrades Palvella Therapeutics (PVLA) - MSN
Can Palvella Therapeutics Inc. stock beat analyst upgradesJuly 2025 Volume & AI Driven Stock Reports - newser.com
Can momentum traders help lift Palvella Therapeutics Inc.2025 Market Sentiment & AI Driven Stock Movement Reports - newser.com
Raymond James upgrades Palvella Therapeutics stock rating to Strong Buy By Investing.com - Investing.com Canada
Why global investors buy Palvella Therapeutics Inc. (PI6) stockIndex Update & Technical Pattern Based Buy Signals - newser.com
Can Palvella Therapeutics Inc. stock maintain growth trajectory2025 Risk Factors & Expert Approved Trade Ideas - newser.com
How geopolitical risks impact Palvella Therapeutics Inc. (PI6) stockQuarterly Portfolio Review & Breakout Confirmation Trade Signals - newser.com
COO Goin Files To Sell 4,302 Of Palvella Therapeutics Inc [PVLA] - TradingView
Palvella Therapeutics (PVLA) Price Target Increased by 39.58% to 115.65 - MSN
Raymond James upgrades Palvella Therapeutics stock rating to Strong Buy - Investing.com India
Can Palvella Therapeutics Inc. stock sustain market leadership2025 Big Picture & Long-Term Capital Growth Ideas - newser.com
What MACD and RSI say about Palvella Therapeutics Inc.Portfolio Return Summary & Real-Time Volume Analysis Alerts - newser.com
Palvella Therapeutics Inc Stock (PVLA) Financials Data
There is no financial data for Palvella Therapeutics Inc (PVLA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):